{
    "nct_id": "NCT04246047",
    "official_title": "DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma",
    "inclusion_criteria": "* Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.\n* Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n* Must have at least 1 aspect of measurable disease, defined as one of the following;\n\n  1. Urine M-protein excretion >=200 mg per 24-hour, or\n  2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or\n  3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).\n* All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Intolerant to daratumumab.\n* Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).\n* Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.\n* Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.\n* Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.\n* Prior allogenic stem cell transplant.\n* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.\n* Corneal epithelial disease.",
    "miscellaneous_criteria": ""
}